On September 15, the "Ernst & Young Fudan Most Potential Enterprise Award Ceremony 2022 and High Growth Enterprise Theme Seminar" hosted by Ernst & Young, the world's leading professional service organization, and the School of Management of Fudan University, a top university in China, kicked off in Shanghai. The "EY Fudan Most Potential Enterprise" list, which has attracted much attention from the industry, was officially announced. After authoritative, professional, and strict screening, Evergreen Therapeutics finally relying on the core founding and management team composed of years of experience in new drug research and development, FDA reviewers, and the industry's top clinical research and development and AI/quantum technology teams, R&D and business models, as well as high-s

On May 28, 2022, Dr. Tom Du, Chairman of Evergreen Therapeutics and Dr. Charles Lee, CMO of Evergreen Therapeutics attended the "First Academic Forum of HwaGen medical thinks markets 2022" sponsored by HwaGen Pharma. The conference was strongly supported by local governments, industry associations and research institutions.Dr. Tom Du making speech Dr. Charles Lee making speech At the meeting, a number of senior experts from the industry witnessed the launch ceremony of the one-stop CRO/CDMO platform of HwaGen Pharma, and discussed the future of small molecule innovative drugs. A roundtable discussion was held on the important role of small molecule new drugs in the fight against COVID-19 and how to better attract financing for innovative drug companies under the current situation

On June 15, the 6th Future Healthcare Top 100 Conference released a series of lists for 2022. This time, Evergreen Therapeutics was successfully awarded the "Top 100 Biomedicine Companies".Evergreen Awarded as "Top 100 Biomedicine Companies" The Future Healthcare Top 100 List was established in 2015. It is the first domestic innovative medical field list for non-listed companies launched by VB100, VBDATA, and Eggshell Research Institute. It aims to select Chinese innovative medical practitioners who truly represent future medical care, discover the core strength of our country's future medical industry, and promote the innovation and transformation process of the healthcare industry. As an international innovative pharmaceutical company founded just over two years ago, E

On February 4, 2022, Evergreen Therapeutics Co., Ltd. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") announced that an oral drug for the treatment of dry macular degeneration with independent intellectual property rights, EG-301, it’s IND was approved by the US FDA and officially entered the phase II clinical trial. EG-301, part of Evergreen Therapeutic’s ophthalmic pipeline, is an oral medication for the treatment of dry maculopathy in patients over 50 years of age. EG-301 has complete safety data in humans and demonstrated efficacy in animal studies. According to statistics, there were about 100 million people with maculopathy in the world in 2020, of which Dry macular disease (AMD) accounted for about 90% of the total number of patients with maculopathy. There